The European Medicines Agency (EMA) has named a series of strategies it plans to implement this year to meet the pharmacovigilance legislation adopted in 2011.
The Agency will continue to review its activities and processes so that it can identify where efficiency gains, re-allocation of resources and reprioritisation of activities may be possible, a media release published today explains.
This should put the Agency in a position to manage its increased responsibilities with existing resources.
In addition, the Work Programme 2012 document says that the EMA will continue reviewing its activities and processes to seek efficiency gains and valuable reallocation of resources and reprioritisation of activities.
The Road Map Implementation Plan names where the Agency plans to strengthen the quality and the regulatory and scientific consistency of its assessment process and outputs.
The Agency also plans to become more transparent, increase efforts to improve communication and increase interaction with stakeholders.